Company intelligence / Profile preview

Muna Therapeutics

Copenhagen, Denmarkmunatherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

Muna Therapeutics has advanced first-in-class small molecule programs targeting neuroinflammation and microglia function. Their lead program includes a TREM2 agonist in IND-enabling studies for early-stage Alzheimer’s disease. The company recently entered a strategic alliance with GSK to leverage its MiND-MAP platform for novel Alzheimer’s drug target identification and validation. No clinical results have been reported yet as the programs are preclinical

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

3 assets

MR-004

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

GSK (strategic alliance for Alzheimer's drug discovery using MiND-MAP platform)Axxam SpA (minority shareholder/target discovery partnership)

Beyond the preview

Go deeper on Muna Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Muna Therapeutics.

Explore the full profile